



Tokyo Stock Exchange  
JASDAQ 4978

**ReproCELL Inc.**

# Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary (Supplemental information)



**November 24, 2015**

As of December 14, 2015, Biopta Limited will become a member of the ReprocCell Group (wholly-owned subsidiary).



Biopta Limited receives human fresh tissues and organs from the UK and the entire US and utilizes them to provide a **drug development support service (outsourcing)** to major pharma manufacturers.

Company: Biopta Limited

CEO: David Bunton




Founded: 2002

Location: Glasgow, Scotland

Subsidiary: Biopta Inc. (United States)


Employees: 18 (group)

## Pharma manufacturer drug development process




### Drug development support service (outsourcing) Rapid market expansion

- Accelerating replacement of high-cost animal experiments with high value experiments using human cells and tissues
- Because experiments using human tissues require specialized techniques and facilities, outsourcing to specialized providers is expanding



R&D cost to pharma manufacturers, broken down by phase of drug development



Global pharma mfr.  
Overall drug development R&D costs  
Approx.  
**58.3 billion USD per year**

**Biopta's main business**

Drug development support service latent global market size  
Approx.  
**14.6 billion USD per year**

出所 : PhRMA : Industry Profileを基にリプロセル作成


Biopta has developed a pioneering drug development support service that encompasses the processes from human tissue procurement through to preclinical laboratory operations. The company has a strong competitive advantage and track record backed by its advanced technology.

## Biopta's main business: Drug development support service (CRO service)

A CRO (Contract Research Organization) is defined as an organization that accepts contracts to undertake research (drug discovery experiments) on behalf of pharmaceutical companies in support of drug development.

### Acquire human fresh tissues · organs

- With UK/US as key locations, has an established network that can timely acquire fresh tissues · organs.






Links with 14 medical institutions in the UK

Delivery network from entire U.S.

### Prediction of drug efficacy and safety using GLP-compliant facilities and strong technological capabilities

- Has prepared equipment and systems compliant with GLP (Good Laboratory Practice), and has accumulated advanced technical capabilities and expertise in their operation.




※GLP: Guidelines that should be complied with to ensure reliability in preclinical investigations.

### Provider network to major pharma mfrs

- Boasts a **track record of transactions (in sales) with 8 of the top 10 Big-pharma companies** that are expanding globally. Has formed a strong customer base.



Taking synergistic advantage of the business superiority of both companies, we will build a strong business portfolio as we move to enter regenerative medicine.



The Reprocell Group welcomes Biopta as we aim to further expand existing business while also aiming to become a leader in the high business potential field of regenerative medicine.

